143B m.8993T>G isogenic mTUNE mT80 Cell Line
Invented by Payam Gammage at Cancer Research UK Glasgow: The Beatson Institute
143B m.8993T>G isogenic mTUNE mT10 Cell Line
Invented by Payam Gammage
Invented at Cancer Research UK Glasgow: The Beatson Institute
- Datasheet
- References (6)
- Inventor Info
Info
| Catalogue Number | 160453 |
| Antigen/Gene or Protein Targets | m.8993T>G |
| Parental Line | 143B |
| Synonyms | mTUNE 10, mT10 |
| Host | Human |
| Tissue | Bone |
| Disease Keywords | Bone cancer, mitochondria, osteosarcoma, |
| Model | Tumour line |
| Relevance |
The cellular metabolic environemnt is influenced by relative levels of coexistant mutant and wild-type mitochondrial DNAs (heteorplasmy) in a range of diseases for which mitochondrial dysfunction is a feature. Disease phenotypes may be rescued by returning heteroplasmy towards wild-type levels. To investigate this approach, the team led by Payam Gammage have devised a series of cell lines which stably express stable levels of mutatnt m.8993T>G mtDNA heteroplasmy. Cell lines bearing m.8993T>G heteroplasmy of 80, 45, and 10% are available at Ximbio. These lines are derivatives of the m.8993T cybrid cell developed by Prof Eric Schon, and are of of 143B human osteosarcoma lineage. |
| Production Details | mTUNE cells were generated by Dr Michal Minczuk’s lab and derive from female human osteosarcoma 143B (RRID: CVCL_2270) cybrid cells (Porteous et al., 1998), after correction of m.8993T>G mutation with mitochondrially-targeted zinc finger nucleases (Gammage et al., 2016a). See Gaude et al., 2018 for further details. |
| Research Area | Cancer, Metabolism |
| Recommended Growing Conditions | Avoid unnecessary freeze/thaw cycles and keep passage duration to below 2-3 months to avoid heteroplasmy shifts. |
| Notes | This is part of a series of three cell line (mTUNE); see Related Reagents tab. |
143B m.8993T>G isogenic mTUNE mT45 Cell Line
Invented by Payam Gammage at Cancer Research UK Glasgow: The Beatson Institute
References: 6 entries
Gammage et al. 2018. Nat Med. 24(11):1691-1695. PMID: 30250142.
Gammage et al. 2018. Methods Mol Biol. 1867:43-56. PMID: 30155814.
Gaude et al. 2018. Mol Cell. 69(4):581-593.e7. PMID: 29452638.
Gammage et al. 2016. Methods Mol Biol. 1351:145-62. PMID: 26530680.
Gammage et al. 2016. Nucleic Acids Res. 44(16):7804-16. PMID: 27466392.
Gammage et al. 2014. EMBO Mol Med. 6(4):458-66. PMID: 24567072.
Add a reference
References: 6 entries
Gammage et al. 2018. Nat Med. 24(11):1691-1695. PMID: 30250142.
Gammage et al. 2018. Methods Mol Biol. 1867:43-56. PMID: 30155814.
Gaude et al. 2018. Mol Cell. 69(4):581-593.e7. PMID: 29452638.
Gammage et al. 2016. Methods Mol Biol. 1351:145-62. PMID: 26530680.
Gammage et al. 2016. Nucleic Acids Res. 44(16):7804-16. PMID: 27466392.
Gammage et al. 2014. EMBO Mol Med. 6(4):458-66. PMID: 24567072.
Add a reference
Inventor Information
Inventors
|
Payam Gammage |
